Cybin CEO Michael Halstead reports purchasing 100,000 common shares at a weighted average price of $13.4705

Cybin Chief Executive Officer Michael Halstead reported purchasing 100,000 Cybin common shares on September 21, 2026, in a transaction disclosed through SEC Form 4. The shares were acquired at a reported weighted average price of $13.4705, with individual purchase prices ranging from $13.395 to $13.53. Following the transaction, Halstead directly beneficially owned 168,568 common shares. The filing identifies the issuer as Cybin Inc., ticker CYBN, and contains no reported derivative securities transaction. The disclosure is an insider ownership filing and does not provide additional information about Cybin's operations, clinical programs, financial outlook, or the rationale for the purchase.